Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 9-15

  Fantus, Daniel ^a   Awan, Zuhier ^b   Seidah, Nabil G ^b   Genest, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Animal models; Arterial calcification; Atherosclerosis; Familial hypercholesterolemia; Low density lipoprotein receptor; Osteoblasts

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AORTA CALCIFICATION; AORTA DISEASE; ATHEROSCLEROSIS; BONE DEVELOPMENT; CALCIFICATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELETION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; INHIBITION KINETICS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANIMALS; AORTIC DISEASES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MICE; RECEPTORS, LDL; VASCULAR CALCIFICATION;

EID: 84871399547     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.026     Document Type: Review

References (58)

1. Messika-Zeitoun D., Bielak L.F., Peyser P.A., et al. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol 2007, 27(3):642-648.
2. Kaplan N.M. Clinical hypertension 2002, Williams and Wilkins, Philadelphia, Lippincott, p. 4. 8th ed.
3. Butany J., Collins M.J., Demellawy D.E., et al. Morphological and clinical findings in 247 surgically excised native aortic valves. Can J Cardiol 2005, 21:747-755.
4. Nkomo V.T., Gardin J.M., Skelton T.N., et al. Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005-1011.
5. Akat K., Borggrefe M., Kaden J.J. Aortic valve calcification: basic science to clinical practice. Heart 2009, 95:616-623.
6. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease: cardiovascular health study. J Am Coll Cardiol 1997, 29:630-634.
7. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
8. Giachelli C.M. Vascular calcification mechanisms. JASN 2004, 2959-2964.
9. Ferket B.S., Genders T.S., Colkesen E.B., et al. Systematic review of guidelines on imaging of asymptomatic coronary artery disease. J Am Coll Cardiol 2011, 57(15):1591-1600. [Review].
10. Mizobuchi M., Towler D., Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. JASN 2009, 1453-1464.
11. Coates T., Kirkland G.S., Dymock R.B., et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998, 32:384-391.
12. Awan Z., Alrasadi K., Francis G.A., et al. Vascular calcification in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008, 28:777-785.
13. Alrasadi K., Alwaili K., Awan Z., Valenti D., Couture P., Genest J. Aortic calcification in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. Heart J 2009, 157:171-176.
14. Shao J.S., Cheng S.L., Sadhu J., Towler D.A. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 2010, 55:579-592.
15. Sage A.P., Tintut Y., Demer L.L. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010, 7:528-536.
16. Johnson R.C., Leopold J.A., Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006, 99:1044-1059.
17. Sato K., Urist M.R. Induced regeneration of calvaria by bone morphogenetic protein (BMP) in dogs. Clin Orthop Relat Res 1985, 197:301-311.
18. Otsuru S., Tamai K., Yamazaki T., Yoshikawa H., Kaneda Y. Bone marrow-derived osteoblast progenitor cells in circulating blood contribute to ectopic bone formation in mice. Biochem Biophysical Res Commun 2007, 354:453-458.
19. Kubota T., Michigami T., Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009, 27:265-271.
20. Bostrom K., Watson K.E., Horn S., Wortham C., Herman I.M., Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993, 91:1800-1809.
21. Luo J., Chen J., Deng Z.L., et al. Wnt signaling and human diseases: what are the therapeutic implications?. Lab Invest 2007, 87:97-103.
22. Rajamannan N.M. Mechanisms of aortic valve calcification: the LDL density radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 2010, 298:5-15.
23. Shao J.S., Cheng S.L., Pingsterhaus J.M., Charlton-Kachigian N., Loewy A.P., Towler D.A. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005, 115:1210-1220.
24. Awan Z., Denis M., Bailey D., et al. The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis 2011, 219:455-462.
25. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
26. Lencel P., Delplace S., Pilet P., et al. Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest 2011, 91:1434-1442.
27. Keuylian Z., De Baaij J.H., Glorian M., et al. The notch pathway attenuates interleukin 1β (IL1β)-mediated induction of adenylyl cyclase 8 (AC8) expression during vascular smooth muscle cell (VSMC) trans-differentiation. J Biol Chem 2012; May 21.
28. Alexander M.R., Murgai M., Moehle C.W., Owens G.K. Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. Physiol Genomics 2012, 44:417-429.
29. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix gla protein. Nature 1997, 386:78-81.
30. Yao Y., Watson A.D., Ji S., Bostrom K.I. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix gla protein. Circ Res 2009, 105:575-584.
31. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross sectional study. Lancet 2003, 361:827-833.
32. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
33. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia. Annu Rev Genet 1990, 24:133-170.
34. Scriver C.R. Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2001, 2:69-101.
35. Humphries S.E., Whittall R.A., Hubbart C.S., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
36. Tosi I., Toledo-Leiva P., Neuwirth C., Naoumova R.P., Soutar A.K. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith hospital lipid clinic. Atherosclerosis 2007, 194:102-111.
37. Thompson G.R., Miller J.P., Breslow J.L. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ (Clin Res Ed) 1985, 291:1671-1673.
38. Naoumova R.P., Thompson G.R., Soutar A.K. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004, 15:413-422. [Review].
39. Thompsen J., Thompson P.D. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
40. Grenon S.M., Lachapelle K., Marcil M., Omeroglu A., Genest J., de Varennes B. Surgical strategies for severe calcification of the aorta (porcelain aorta) in two patients with homozygous familial hypercholesterolemia. Can J Cardiol 2007, 23:1159-1161.
41. Saito S., Usui A., Akita T., Ueda Y. Surgery for calcific aortic root stenosis in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg 2006, 29:114-116.
42. Yasuda T., Kawasuji M., Sakakibara N., Watanabe Y. Aortic valve replacement for the calcified ascending aorta in homozygous familial hypercholesterolemia. Eur J Cardiothorac Surg 2000, 18:249-250.
43. Teo K.K., Corsi D.J., Tam J.W., Dumesnil J.G., Chan K.L. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol 2011, 27(6):800-808.
44. Weiss R.M., Ohashi M., Miller J.D., Young S.G., Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
45. Clarkson T.B., Bond M.G., Bullock B.C., Marzetta C.A. A study of atherosclerosis regression in Macaca mulatta. Exp Mol Pathol 1984, 34:345-368.
46. Kawata K., Eguchi T., Kubota S., et al. Possible role of LRP1, a CCN2 receptor, in chondrocytes. Biochem Biophys Res Commun 2006, 345(2):552-559.
47. Kim D.H., Inagaki Y., Suzuki T., et al. A new low-density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem 1998, 124:1072-1076.
48. Fujinoa T.H., Asabab M.J., Kang Y., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. PNAS 2003, 100:229-234.
49. Mani A., Radhakrishnan J., Wang H., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
50. Ye Z.J., Go G.W., Singh R., Liu W., Keramati A.R., Mani A. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J Biol Chem 2012, 287(2):1335-1344.
51. Niemeier A., Niedzielska D., Secer R., et al. Uptake of postprandial lipoproteins into bone in vivo: impact on osteoblast function. Bone 2008, 43:230-237.
52. Tintut Y., Morony S., Demer L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arter Thromb Vasc Biol 2004, 24:e6-10.
53. Parhami F., Morrow A.D., Balucan J., et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. Arter Thromb Vasc Biol 1997, 17:680-687.
54. Awan Z., Alwaili K., Alshahrani A., Langsetmo L., Goltzman D., Genest J. Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification. Clin Chem 2010, 56:1599-1607.
55. Wallin R., Wajih N., Greenwood G.T., Sane D.C. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001, 21(4):274-301.
56. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 2011, 162(4):597-605.
57. Schmidt H.H., Hill S., Makariou E.V., Feuerstein I.M., Dugi K.A., Hoeg J.M. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol 1996, 77:575-580.
58. Gill E.A. Does statin therapy affect the progression of atherosclerosis measured by a coronary calcium score?. Curr Atheroscler Rep 2010, 12(2):83-87.